Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
845264-92-8
Molecular formula
C3104H4788N856O950S44
Molecular weight
70708.13 g/mol
Drug class
TACI-Fc fusion proteindual B-lymphocyte stimulator (BLyS/BAFF) and APRIL inhibitor biologic
Mechanism of action
A soluble fusion protein comprising the extracellular domain of TACI linked to an Fc region. It binds and neutralises BLyS (BAFF) and APRIL, reducing survival and activation signals for B cells and antibody-producing plasma cells.
Indications / reported uses
Reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression under the US FDA accelerated approval for atacicept-vymj (Trutakna, initial approval 2026). Long-term effect on kidney-function decline was not established in the accelerated-approval label; consult current product information.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Atacicept Environmental Risk Assessment (ERA) (the Atacicept ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.